Alternative splicings on p53, BRCA1 and PTEN genes involved in breast cancer

Biochemical and Biophysical Research Communications

Volumn 413, Issue 3, 2011, Pages 395-399

  Okumura, Naoko ^a   Yoshida, Hitomi ^a   Kitagishi, Yasuko ^a   Nishimura, Yuri ^a   Matsuda, Satoru ^a  

^a NARA WOMEN'S UNIVERSITY   (Japan)

Author keywords

Alternative splicing; BRCA1; Breast cancer; P53; PTEN

Indexed keywords

BRCA1 PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

ALTERNATIVE RNA SPLICING; APOPTOSIS; BREAST CANCER; CELL PROLIFERATION; DNA BINDING; ENZYME ACTIVITY; GLUCOSE METABOLISM; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PROCESSING; RNA SPLICING; SHORT SURVEY; TUMOR SUPPRESSOR GENE;

ALTERNATIVE SPLICING; BRCA1 PROTEIN; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROTEIN CONFORMATION; PROTEIN ISOFORMS; PTEN PHOSPHOHYDROLASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80053377363     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.08.098     Document Type: Short Survey

References (48)

1. Ferreira E.N., Rangel M.C., Galante P.F., et al. Alternative splicing enriched cDNA libraries identify breast cancer-associated transcripts. BMC Genomics 2010, 11(Suppl. 5: S4).
2. Revil T., Gaffney D., Dias C., Majewski J., Jerome-Majewska L.A. Alternative splicing is frequent during early embryonic development in mouse. BMC Genomics 2010, 11:399.
3. Shepard P.J., Hertel K.J. The SR protein family. Genome Biol. 2009, 10(10):242.
4. Misquitta-Ali C.M., Cheng E., O'Hanlon D., et al. Global profiling and molecular characterization of alternative splicing events misregulated in lung cancer. Mol. Cell Biol. 2011, 31(1):138-150.
5. Harries L.W., Perry J.R., McCullagh P., Crundwell M. Alterations in LMTK2, MSMB and HNF1B gene expression are associated with the development of prostate cancer. BMC Cancer 2010, 10:315.
6. Körner M., Miller L.J. Alternative splicing of pre-mRNA in cancer: focus on G protein-coupled peptide hormone receptors. Am. J. Pathol. 2009, 175(2):461-472.
7. Margenthaler J.A. Optimizing conservative breast surgery. J. Surg. Oncol. 2011, 103(4):306-312.
8. Eng C. PTEN: one gene, many syndromes. Hum. Mutat. 2003, 22(3):183-198.
9. Muggia F., Safra T., Dubeau L. BRCA genes: lessons learned from experimental and clinical cancer. Ann. Oncol. 2011, 22(Suppl. 1:i7-10).
10. Blasberg R. PET imaging of gene expression. Eur. J. Cancer 2002, 38(16):2137-2146.
11. Aylon Y., Oren M. New plays in the p53 theater. Curr. Opin. Genet. Dev. 2011, 21(1):86-92.
12. Muller P.A., Vousden K.H., Norman J.C. P53 and its mutants in tumor cell migration and invasion. J. Cell Biol. 2011, 192(2):209-218.
13. Goh A.M., Coffill C.R., Lane D.P. The role of mutant p53 in human cancer. J. Pathol. 2011, 223(2):116-126.
14. Bourdon J.C., Fernandes K., Murray-Zmijewski F., et al. P53 isoforms can regulate p53 transcriptional activity. Genes Dev. 2005, 19(18):2122-2137.
15. Rohaly G., Chemnitz J., Dehde S., Nunez A.M., Heukeshoven J., Deppert W., Dornreiter I. A novel human p53 isoform is an essential element of the ATR-intra-S phase checkpoint. Cell 2005, 122:21-32.
16. Harms K.L., Chen X. The C terminus of p53 family proteins is a cell fate determinant. Mol. Cell Biol. 2005, 25(5):2014-2030.
17. Scoumanne A., Harms K.L., Chen X. Structural basis for gene activation by p53 family members. Cancer Biol. Ther. 2005, 4(11):1178-1185.
18. Courtois S., Verhaegh G., North S., et al. DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 2002, 21(44):6722-6728.
19. Ghosh A., Stewart D., Matlashewski G. Regulation of human p53 activity and cell localization by alternative splicing. Mol. Cell Biol. 2004, 24(18):7987-7997.
20. Slatter T.L., Hung N., Campbell H., et al. Hyperproliferation, cancer, and inflammation in mice expressing a {Delta}133p53-like isoform. Blood 2011, 117(19):5166-5177.
21. Fujita K., Mondal A.M., Horikawa I., et al. P53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat. Cell Biol. 2009, 11(9):1135-1142.
22. Kashkin K.N., Khlgatian S.V., Gurova O.V., Kuprash D.V., Nedospasov S.A. New mutations in the human p53 gene-a regulator of the cell cycle and carcinogenesis. Biochemistry (Mosc) 2007, 72(3):282-292.
23. Flaman J.M., Waridel F., Estreicher A., et al. The human tumour suppressor gene p53 is alternatively spliced in normal cells. Oncogene 1996, 12(4):813-818.
24. den Hollander P., Rayala S.K., Coverley D., Kumar R. Ciz1, a Novel DNA-binding coactivator of the estrogen receptor alpha, confers hypersensitivity to estrogen action. Cancer Res. 2006, 66(22):11021-11029.
25. Okumura N., Nagata Y., Yoshida H., Nishimura Y., Kitagishi Y., Matsuda S. Genistein diminished Ciz1 expression in Daudi lymphoid cells. Int. J. Appl. Biol. Pharm. Tech. 2010, 1:1040-1045.
26. Jiang L., Luo X., Shi J., et al. PDRG1, a novel tumor marker for multiple malignancies that is selectively regulated by genotoxic stress. Cancer Biol. Ther. 2011, 11(6):567-573.
27. Nakopoulou L., Giannopoulou I., Ach Lazaris, et al. The favorable prognostic impact of tissue inhibitor of matrix metalloproteinases-1 protein overexpression in breast cancer cells. APMIS 2003, 111(11):1027-1036.
28. Okumura N., Nishimura Y., Yoshida H., Nagata Y., Kitagishi Y., Matsuda S. Ethanol extract of herb Sage suppressed the TIMP-1 expression in lymphoid culture cells. Asian J. Sci. Technol. 2010, 3:64-66.
29. Dien J., Amin H.M., Chiu N., et al. Signal transducers and activators of transcription-3 up-regulates tissue inhibitor of metalloproteinase-1 expression and decreases invasiveness of breast cancer. Am. J. Pathol. 2006, 169(2):633-642.
30. Sakai T., Furihata T., Kawamata H., et al. Molecular and genetic characterization of a non-metastatic human esophageal cancer cell line, T.Tn expressing non-functional mutated p53. Int. J. Oncol. 2002, 21(3):547-552.
31. Orban T.I., Olah E. Expression profiles of BRCA1 splice variants in asynchronous and in G1/S synchronized tumor cell lines. Biochem. Biophys. Res. Commun. 2001, 280:32-38.
32. Chai Y.L., Cui J., Shao N., Shyam E., Reddy P., Rao V.N. The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter. Oncogene 1999, 18(1):263-268.
33. Mullan P.B., Gorski J.J., Harkin D.P. BRCA1-a good predictive marker of drug sensitivity in breast cancer treatment?. Biochim. Biophys. Acta 2006, 1766(2):205-216.
34. Mullan P.B., Quinn J.E., Harkin D.P. The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene 2006, 25(43):5854-5863.
35. Wang H., Shao N., Ding Q.M., Cui J., Reddy E.S., Rao V.N. BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases. Oncogene 1997, 15(2):143-157.
36. Cui J.Q., Wang H., Reddy E.S., Rao V.N. Differential transcriptional activation by the N-terminal region of BRCA1 splice variants BRCA1a and BRCA1b. Oncol. Rep. 1998, 5(3):585-589.
37. Cui J.Q., Shao N., Chai Y., Wang H., Reddy E.S., Rao V.N. BRCA1 splice variants BRCA1a and BRCA1b associate with CBP co-activator. Oncol. Rep. 1998, 5(3):591-595.
38. Maniccia AW, Lewis C, Begum N, et al., "Mitochondrial Localization, ELK-1 Transcriptional Regulation and Growth Inhibitory Functions of BRCA1, BRCA1a, and BRCA1b proteins," J cell Phisiol, 2009.
39. Sun Lan., Irudayaraj Joseph. Quantitative Surface-Enhanced Raman for Gene Expression Estimation. Biophys. J. 2009, 96:4709-4716.
40. Hollander M.C., Blumenthal G.M., Dennis P.A. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat. Rev. Cancer 2011, 11(4):289-301.
41. Carracedo A., Alimonti A., Pandolfi P.P. PTEN level in tumor suppression: how much is too little?. Cancer Res. 2011, 71(3):629-633.
42. Blumenthal G.M., Dennis P.A. PTEN hamartoma tumor syndromes. Eur. J. Hum. Genet. 2008, 16(11):1289-1300.
43. Soula-Rothhut M., Coissard C., Sartelet H. The tumor suppressor PTEN inhibits EGF-induced TSP-1 and TIMP-1 expression in FTC-133 thyroid carcinoma cells. Exp. Cell Res. 2005, 304(1):187-201.
44. Akahane T., Akahane M., Shah A., Connor C.M., Thorgeirsson U.P. TIMP-1 inhibits microvascular endothelial cell migration by MMP-dependent and MMP-independent mechanisms. Exp. Cell Res. 2004, 301(2):158-167.
45. Agrawal S., Eng C. Differential expression of novel naturally occurring splice variants of PTEN and their functional consequences in Cowden syndrome and sporadic breast cancer. Hum. Mol. Genet. 2006, 15(5):777-787.
46. Sarquis M.S., Agrawal S., Shen L., Pilarski R., Zhou X.P., Eng C. Distinct expression profiles for PTEN transcript and its splice variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome. Am. J. Hum. Genet. 2006, 79(1):23-30.
47. Liu Y., Malaviarachchi P., Beggs M., Emanuel P.D. PTEN transcript variants caused by illegitimate splicing in "aged blood samples and EBV-transformed cell lines" Hum. Genet. 2010, 128(6):609-614.
48. Kalnina Z., Zayakin P., Silina K., Line A. Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer 2005, 42(1):342-357.